Across TCGA pan-cancer cohorts, HSPE1P16 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of HSPE1P16’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where HSPE1P16 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types HSPE1P16 is over-expressed in tumor.
PRAD and LUSC are the cancer types where HSPE1P16 tumor–normal differential expression is most reproducible.